Fingerprint
Dive into the research topics of 'A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS ≥1% metastatic NSCLC'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically